# Apabetalone for Pulmonary Arterial Hypertension

> **NCT04915300** · PHASE2 · UNKNOWN · sponsor: **Laval University** · enrollment: 72 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Apabetalone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04915300
- **Lead sponsor:** Laval University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915300, "Apabetalone for Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04915300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*